Long term efficacy and safety of a generic atorvastatin in usual clinical care setting

Medical Journal of Malaysia

Volumn 66, Issue 3, 2011, Pages 214-219

  Ong, L M ^a   Punithavathi, N ^a   Lena, Y L L ^a   Mahanim, O ^a   Leekha, S ^b  

^a Penang Hospital   (Malaysia)

^b Ranbaxy ^*  (Malaysia)

Author keywords

3 hydroxy 3methylglutaryl coenzyme a (hmg coa) reductase inhibitors; Coronary heart disease (chd); Hypercholesterolaemia; Long term efficacy; Real life clinical setting

Indexed keywords

ATORVASTATIN; LOW DENSITY LIPOPROTEIN;

ABDOMINAL PAIN; ACUTE CORONARY SYNDROME; ACUTE LIVER FAILURE; ADULT; AGED; ARTHRALGIA; ARTICLE; BRAIN DISEASE; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCULOSKELETAL PAIN; PATIENT CARE; PATIENT COMPLIANCE; PRURITUS; RHABDOMYOLYSIS; SIDE EFFECT;

ADULT; AGED; CHOLESTEROL, LDL; DRUG ADMINISTRATION SCHEDULE; DRUGS, GENERIC; FEMALE; FOLLOW-UP STUDIES; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; PYRROLES;

EID: 80054107692     PISSN: 03005283     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Genest J, Frohlich J, Fodor G, McPherson R. Working Group on Hypercholesterolemia and Other Dyslipidemias. Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: Summary of the 2003 update. CMAJ. 2003; 169: 921-4. (Erratum in 2003; 169: 1149).
2. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med. 1998; 339: 1349-57.
3. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998; 279: 1615-22.
4. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996; 335: 1001-9.
5. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995; 333: 1301-7.
6. Malhotra HS, Goa KL. Atorvastatin: an updated review of its pharmacological properties and use in dyslipidaemia: Drugs. 2001: 61(12): 1835-8. Adis International Limited, Mairangi Bay, Auckland, New Zealand.
7. Sameerah S.A.R, Sarojini S. (Eds). Malaysian Statistics on Medicine 2005. Kuala Lumpur 2007.
8. Punithavathi N, Ong LM, Lena YLL, Leekha S et al. A multicentre study in Malaysia to determine the efficacy and safety of a generic atorvastatin. Med J Malaysia. 2009; 150-4.
9. Peter P. Roy-Byrne, M.D., Cathy D. Sherbourne, Ph.D., Michelle G. Craske, Ph.D. et al. Moving Treatment Research From Clinical Trials to the Real World. Psychiatric Services. 2003; 327-32.
10. Pinching AJ; Australasian Society for HIV Medicine. Conference. Annu Conf Australas Soc HIV Med. 1994 Nov 3-6; 6: 88. (unnumbered abstract). Department of Immunology, Medical College of Saint Bartholomew's Hospital, West Smithfield, London, UK.
11. Van Dam M, Zwart M, de Beer F. et al. Long term efficacy and safety of atorvastatin in the treatment of severe type III and combined dyslipidaemia. Heart. 2002 Sep; 88(3): 234-8.
12. Noseda G, Darioli R, Keller U, et al. [evaluating the efficacy and tolerance of atorvastatin in hyperlipidaemia in general practice (SWITCH Study)] Ospedale Regionale della Beata Vergine, Mendrisio [article in German]
13. Braunholtz DA, Edwards SLJ, Lilford R. Are randomised trials good for us? Evidence for a trial effect. J Clin Epidemiol 2001; 54: 217-24.
14. De Amici D, Klersy C, Ramajoli F, et al. Impact of the Hawthorne effect in a longitudinal clinical study. The case for anaesthesia. Controlled clin Trials 2000; 21: 103-14.
15. J West, J Wright, D Tuffnell, D Jankowicz, R West. Do clinical trials improve quality of care? A comparison of clinical processes and outcomes in patients in a clinical trial and similar patients outside a trial where both groups are managed according to a strict protocol. Qual Saf Health Care 2005; 14: 175-8. doi: 10.1136/qshc.2004.011478.
16. Caspard H, Chan AK, Walker AM. The long-term course of low-density lipoprotein cholesterol after initiation of statin treatment: retrospective database analysis over 3 years in health maintenance organization enrollees. Clin Ther. 2005 Oct: 27(10): 1622-8.
17. Brown AS, Bakker-Arkema, Yellin L, et al. Treating patients with documented atherosclerosis to National Cholesterol Education Programrecommended low-density-lipoprotein cholesterol goals with atorvastatin, fluvastatin, lovastatin and simvastatin. J Am Coll Cardiol 1998; 32: 665-72.
18. Atorvastatin Study Group I. - Davidson M. Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia. - Am J Cardiol - 1-JUN-1997; 79(11): 1475-81.
19. UK Medicines Information Pharmacists Group- Therapeutic class summaries- UKMI. "Statins", 2003.
20. Stein EA. Comparison of statins in hypertriglyceridemia. - Am J Cardiol - 26-FEB-1998; 81(4A): 66B-69B
21. Carmelo V. Venero, Paul D. Thompson. Managing Statin Myopathy Endocrinology & Metabolism Clinics of North America, Volume 38, Issue 1, March 2009, Pages 121-136.
22. A James McKenney, PharmD, Ed. Summary of 'The Report of the National Lipid Association Statin Safety Task Force - Am J Cardiol. 2006; 97: Supplement.
23. McKenny JM, Davidson, MH, Jacobson TA, et al. Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force. Am J Cardiol. 2006; 97 (suppl 8A): 89C-94C.
24. David D. Waters. Safety of High-Dose Atorvastatin Therapy The American Journal of Cardiology, 2005; 96(Issue 5) Suppl 1: 69-75.
25. Donald M. Black, MD; Rebecca G. Bakker-Arkema, MS; James W. Nawrocki, MS. An Overview of the Clinical Safety Profile of Atorvastatin (Lipitor), a New HMG-CoA Reductase Inhibitor. Arch Intern Med. 1998; 158: 577-584.
26. Illingworth DR, Tobert JA. A review of clinical trials comparing HMG-CoA reductase inhibitors. Clin Ther. 1994;16: 366-85.